17 completed, 8 recruiting, 7 not yet recruiting, 4 active not recruiting. 13 Phase 3, 12 Phase 2, 7 Phase 4, 2 Phase 1.
Follow Rimegepant: new trials by email Literature Review of Rimegepant trials Research Report on Rimegepant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Open-Label, Multi-Center Study of Vestibular Migraine Prevention: Rimegepant Versus Flunarizine Non-inferiority Study Rimegepant, Flunarizine - Vestibular Migraine | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 400 | 2026-12-01 | 2026-08-07 |
| Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma Rimegepant, Tislelizumab, Nab-paclitaxel - Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC) | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 220 | 2026-10-01 | 2026-09-10 |
| A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine Rimegepant, Placebo - Preventive Treatment of Migraine | Phase 3 | Recruiting | Pfizer | 400 | 2026-08-26 | 2026-10-14 |
| Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard Therapy Rimegepant, Toripalimab - Advanced Urothelial Carcinoma | Phase 1 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 12 | 2026-07-06 | 2026-09-22 |
| A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department Rimegepant, Zavegepant - Migraine, Migraine Disease | Phase 1 | Not yet recruiting | University of South Florida | 100 | 2026-07-01 | 2026-06-25 |
| A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine Rimegepant - Acute Treatment of Migraine | Phase 4 | Recruiting | Pfizer | 400 | 2026-05-28 | 2026-10-14 |
| Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL Rimegepant, Glofitamab, Obinutuzumab - Relapsed/Refractory Large B-cell Lymphoma (LBCL) | Phase 2 | Not yet recruiting | Ruijin Hospital | 100 | 2026-05-01 | 2026-05-29 |
| Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients Rimegepant, PD-1 - Colon Cancer | Phase 2 | Not yet recruiting | Fudan University | 20 | 2025-07-01 | 2025-05-31 |
| Acute Migraine Treatment in the ED With Gepants Rimegepant, Zavegepant - Migraine Headaches | Phase 4 | Terminated | Icahn School of Medicine at Mount Sinai | 9 | 2025-06-05 | 2026-04-29 |
| The R-E-V-I-V-A-L Study Rimegepant, Placebo - Vestibular Migraine | Phase 2 | Active not recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 240 | 2025-06-01 | 2025-06-25 |
| A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experiment Rimegepant, Placebo - Vestibular Migraine, Adults 18 Years and Older (no Other Exclusion Criteria) | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 240 | 2025-06-01 | 2025-05-14 |
| A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine Rimegepant, Placebo Comparator, Standard of Care - Menstrual Migraine | Phase 3 | Recruiting | Pfizer | 723 | 2025-03-11 | 2026-07-09 |
| The Real-world Study of Rimegepant Treatment in Female Migraine Patients of China Rimegepant - Migraine, Migraine Prophylaxis | Not yet recruiting | The First Affiliated Hospital of Soochow University | 300 | 2024-12-01 | 2024-12-11 | |
| A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine Rimegepant, Placebo - Migraine | Phase 3 | Active not recruiting | Pfizer | 200 | 2024-11-15 | 2026-07-30 |
| Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey Rimegepant, Triptans - Migraine | Completed | Pfizer | 1395 | 2024-10-10 | 2026-01-22 | |
| A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache Rimegepant, Rizatriptan Benzoate - Migraine | Phase 4 | Recruiting | Antonios Likourezos | 80 | 2024-09-01 | 2026-09-24 |
| ARISE-A Chinese Real-world Study of Rimegepant for the Acute Treatment of Migraine Rimegepant - Migraine | Active not recruiting | Chinese PLA General Hospital | 3000 | 2024-08-27 | 2026-02-06 | |
| Migraine Medication Effects on Urinary Symptoms Ubrogepant, Rimegepant, Atogepant - Overactive Bladder, Bladder Pain Syndrome | Enrolling by invitation | The Cleveland Clinic | 200 | 2024-04-05 | 2026-10-19 | |
| RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment Rimegepant 75 mg - Migraine, Migraine With Aura | Recruiting | University of Florence | 100 | 2024-03-26 | 2026-06-11 | |
| A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area Rimegepant - Migraine | Completed | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 120 | 2024-01-26 | 2026-05-22 |
Showing 20 of 41. Sign in to see all of them.
Migraine Disorders (27) · Headache (5) · Hyperacusis (3) · Photophobia (3) · Migraine with Aura (2) · Migraine without Aura (2) · Nausea (2) · Pain (2) · Cluster Headache (1) · Colonic Neoplasms (1) · Cystitis, Interstitial (1) · Emergencies (1) · Headache Disorders, Secondary (1) · Psoriasis (1) · Recurrence (1)
Pfizer (23) · Second Affiliated Hospital, Zhejiang University, School of Medicine (3) · Antonios Likourezos (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chinese PLA General Hospital (1) · Eli Lilly and Company (1) · Fudan University (1) · Icahn School of Medicine at Mount Sinai (1) · Mayo Clinic (1) · Ruijin Hospital (1) · Shanghai Zhongshan Hospital (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · The Cleveland Clinic (1) · The First Affiliated Hospital of Soochow University (1) · University of Florence (1)
United States (26) · China (12) · Italy (6) · Canada (5) · Poland (5) · Spain (5) · Japan (4) · Denmark (3) · Finland (3) · Germany (3) · Mexico (3) · United Kingdom (3) · Australia (2) · Austria (2) · Belgium (2)
Carrie Robertson, MD (1) · Howard B Goldman, MD (1) · Jonathan Schimmel (1) · Richard D Granstein, MD (1) · Sergey Motov, MD (1)
PMID 31311674, PMID 36739511, PMID 37210098, PMID 41652666, PMID 42839212, PMID 11222783, PMID 26224714, PMID 30020261, PMID 36946234, PMID 37042545, PMID 37073858, PMID 39344988, PMID 41235617, PMID 23965396, PMID 31291516, PMID 31932515, PMID 33338437, PMID 34455556, PMID 35038983, PMID 36125279, PMID 36417057, PMID 38174577, PMID 38627638, PMID 38659334, PMID 38764606, PMID 38985436, PMID 39070853, PMID 39520634, PMID 40542538, PMID 40583813, PMID 40629887, PMID 41204073, PMID 41255093, PMID 41255098, PMID 41366286, PMID 41430107, PMID 41761058, PMID 41930741, PMID 42047365, PMID 42802816, PMID 42816745, PMID 42828704
2023 (1)